Preview Newsletter

XARELTO Media Monitoring – Week of 11-20-15

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Seeger Weiss LLP Reports That Xarelto Multidistrict Litigation Bellwether Trial Dates Set For Early 2017
Nov 13, 2015 | PR Newswire
By Seeger Weiss LLP

Seeger Weiss LLP is reporting that the bellwether trial dates have been set for the Xarelto Multidistrict Litigation (MDL). Presiding District Court Judge Eldon Fallon has issued an order for the first four scheduled bellwether trials to commence. The first two will be held in the Eastern District of Louisiana; the first starting on February 6, 2017, and the second starting on March 13, 2017. The next trial will be held in Mississippi on April 24, 2017. The fourth will be held in Texas on May 30, 2017.
Xarelto Lawsuit Update: Case Numbers Rising in Philadelphia Mass Tort Group
Nov 13, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports today on the development of the Philadelphia mass tort group that was created for the ongoing Xarelto litigation. The Philadelphia mass tort group was created after a motion was made to consolidate the growing number of cases filed against the manufacturers of Xarelto in the area. There are currently 478 cases filed in the mass tort group. The number of cases filed has consistently been on the rise and is expected to continue to grow as time moves on.
Xarelto Lawsuit Alleges Drug Caused Father’s Death
Nov 15, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on a Vermont lawsuit filed against Xarelto manufacturers Bayer AG and Janssen (a subsidiary of Johnson & Johnson). The suit was filed under case number 2:14-cv-00159-CR in the state’s federal court by a young woman who lost her father when he passed away from complications due to uncontrollable bleeding. The complaint filed alleges that blood thinning drug Xarelto caused the man’s uncontrollable bleeding and subsequent death.
Legal-Bay Lawsuit Settlement Funding Reports Xarelto News: Bellwether Trial Dates Announced
Nov 16, 2015 | pharmiweb.com
By Legal Bay

Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the first bellwether trial dates in the Xarelto multidistrict litigation have been announced. U.S. District Judge Eldon Fallon will be overseeing the cases, and an order states that cases will be selected in January of 2016 from 40 lawsuits. Cases will be selected according to readiness for trial. According to an article on Reuters, the first two trials will take place in the U.S. District Court in the Eastern District of Louisiana on February 6th and March 13th of 2017. The third trial will be heard in Mississippi on April 24th, 2017 and the fourth will take place in Texas on May 30th, 2017.
Xarelto Lawsuit Bellwether Trial Updates
Nov 16, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on the latest news concerning Xarelto lawsuit bellwether trials. These trials are being overseen by United States District Judge Eldon Fallon. A recent order additionally states that bellwether trial cases will be selected in January of 2016 from a group of 40 filed suits. The selections will be made based on which seem most ready for trial. It has been announced that the first 2 of 4 bellwether trials will take place in the U.S. District Court of the Eastern District of Louisiana on February 6th, 2017, and March 13th, 2017. The third Xarelto bellwether trial is set to be heard in Mississippi on April 24th,2017, while the fourth and final bellwether trial will be heard in Texas on May 30th,2017.
Xarelto Lawsuit Questions Drug’s Once-Daily Dosage
Nov 17, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on a new type of Xarelto lawsuit which was filed in Pennsylvania State Court. The suit, filed against Janssen Pharmaceuticals (a division of Johnson & Johnson), brings a new argument to the table against blood-thinner Xarelto. It alleges that the recommended once-daily dosage of the drug is not effective for 24-hours as indicated. Supporting evidence of this is found in details of the suit, which discuss a plaintiff who suffered a stroke just four days after starting to use Xarelto in order to prevent a stroke due to his atrial fibrillation condition.
Xarelto Lawsuit Update: Information About Statute of Limitations for Xarelto Cases
Nov 17, 2015 | KUSA-TV
By Marc Goldich

BloodThinnerHelp.com reports today with information on the statute of limitations for Xarelto lawsuits. The statute of limitations are especially important to be aware of because they vary from state to state and once they expire, the plaintiff is barred from bringing a Xarelto lawsuit forward.
Xarelto Lawsuit Update: New Xarelto MDL Pretrial Order Released
Nov 17, 2015 | KFJX-TV
By Marc Goldich

BloodThinnerHelp.com reports today with an update from the Xarelto multidistrict litigation. On October 21, 2015, Pretrial Order 15B was released by presiding Judge Eldon Fallon. The order is in regards to the preservation of voice mail, text messages, and instant messages that may be pertinent to the Xarelto litigation.
Xarelto Lawsuit Alleges Drug Caused Vermont Man's Parenchymal Hemorrhage And Death
Nov 17, 2015 | WHNS-TV
By Marc Goldich

BloodThinnerHelp.com reports on details from another lawsuit filed against blood-thinning drug Xarelto and manufactureres Janssen Pharmaceuticals and Bayer AG. The suit is just one of many which similarly allege that Xarelto causes uncontrollable bleeding that can lead to severe injury or death. The suit was filed under case number 2:14-cv-00159-cr in Vermont federal court on July 25th of last year. It was filed by a daughter for her father, who had died due to a parenchymal hemorrhage which his family alleges was caused by his use of Xarelto.
Xarelto Lawsuit Update: Information About Statute of Limitations for Xarelto Cases
Nov 17, 2015 | KUSA-TV
By Marc Goldich

BloodThinnerHelp.com reports today with information on the statute of limitations for Xarelto lawsuits. The statute of limitations are especially important to be aware of because they vary from state to state and once they expire, the plaintiff is barred from bringing a Xarelto lawsuit forward.
Xarelto Lawsuit Updates Show An Increase In Mass Tort Filings
Nov 18, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on recent developments showing an increase in the lawsuits filed against blood-thinner Xarelto in Philadelpha’s mass tort group. The group was created in Philadelphia, Pennsylvania after a motion was made to consolidate the growing cases, which now number around 478. Federally, they are joined by over 1,700 cases filed against the drug. All cases similarly allege that Xarelto causes uncontrollable bleeding. Since this consolidation and the formation of MDL 2592 with all federal cases, additional cases have been increasingly appearing.
Xarelto Lawsuit Plaintiff Seeks Compensation From Manufacturers
Nov 19, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on another lawsuit filed against blood-thinning drug Xarelto, as well as drug developers, researchers, and manufacturers Bayer AG and Johnson & Johnson which alleges that they fraudulently misrepresented risks, dangers, and benefits associated with the drug. This particular filing was a 32-count complaint. It was filed on October 13th in St. Clair County Circuit Court.
Xarelto Lawsuit Numbers Explode According To Court Documents
Nov 19, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports on the recent surge of Xarelto uncontrollable bleeding lawsuits, according to numbers from court documents. It was reported that in August alone, 400 cases were filed. Those involved in the litigation anticipate that additional claims will continue to be filed as time goes by.
Xarelto Lawsuit Plaintiff Seeks Compensation From Manufacturers
Nov 19, 2015 | KOLD-TV
By Marc Goldich

BloodThinnerHelp.com reports on another lawsuit filed against blood-thinning drug Xarelto, as well as drug developers, researchers, and manufacturers Bayer AG and Johnson & Johnson which alleges that they fraudulently misrepresented risks, dangers, and benefits associated with the drug. This particular filing was a 32-count complaint. It was filed on October 13th in St. Clair County Circuit Court.
Xarelto Lawsuit Plaintiffs Note 4 Years Later, Still No Antidote
Nov 20, 2015 | WHNS-TV
By Marc Goldich

BloodThinnerHelp.com reports on Xarelto lawsuits filed, which now total more than 2,000 cases nationally. These cases are comprised of over 1,700 federal filings, which have been consolidated to form multidistrict litigation number 2592, as well as around 500 cases in Philadelphia, Pennsylvania’s mass tort group. Lawsuits across the board similarly allege that blood-thinner Xarelto causes uncontrollable bleeding episodes, which have sometimes resulted in death.
Xarelto Lawsuit Plaintiffs Question Lack of Antidote
Nov 20, 2015 | KFMB-TV
By Marc Goldich

BloodThinnerHelp.com reports on lawsuits filed against Bayer AG and Janssen Pharmaceuticals (a division of pharmaceutical conglomerate Johnson & Johnson), which question blood-thinning drug Xarelto’s market release without corresponding antidote. The suits note that the lack of antidote, which is still the case today, is irresponsible and negligent. The drug, despite it’s lack of antidote, has been on the market for four years now, and has also become the subject of an increasing number of lawsuits which connect it to uncontrollable bleeding and death.

Plaintiff Attorney Blog Posts

Lawsuit: Xarelto Caused Gastrointestinal Bleeding
Nov 13, 2015 | Top Class Actions
By Joanna Szabo

A Tennessee woman who developed gastrointestinal bleeding two weeks after first taking Xarelto filed a Xarelto bleeding lawsuit against Janssen Research and Development. Plaintiff Judy S. alleges in her lawsuit that taking Xarelto caused the severe gastrointestinal bleeding that led to hospitalization and continuing treatment.
Hawaii Xarelto Bleeding Events Lawsuit
Nov 17, 2015 | Blood Thinner Help
By Marc Goldich

Xarelto is a popular anticoagulant on the market that is marketed as “one-size-fits-all” type of drug, unlike the older anticoagulants, like Warfarin that require multitudes of doctors visits and blood tests to get the correct dosage per person.
Xarelto Bleeding Lawsuit Alleges Drug Caused Wrongful Death
Nov 19, 2015 | Top Class Actions
By Tamara Burns

A woman in Rhode Island is suing Janssen Pharmaceuticals and parent company Johnson & Johnson on behalf of her late husband who allegedly suffered personal injury and later died as a result of using the anticoagulant drug Xarelto.
Considering a Xarelto lawsuit? Our Dallas Xarelto lawyers will help you stand up to giant companies and get just compensation. No win no fee!
Nov 19, 2015 | Mullen & Mullen

Xarelto is marketed by Johnson & Johnson, a subsidiary of Janssen Pharmaceuticals, and is manufactured by Bayer. Designed to treat and prevent blood clots, Xarelto (rivaroxaban) unfortunately sometimes does exactly the opposite. Instead, Xarelto can cause you to bleed internally – to the point where it’s fatal.
Louisiana Xarelto Wrongful Death Lawsuit
Nov 19, 2015 | The Legal Examiner
By Shexad Malik MD JD

In the latest of recently filed cases, Ashlie Fluitt from Louisiana, filed a wrongful death claim on behalf of her grandmother who died as a result of catastrophic side effects from using Xarelto. According to the lawsuit, it is alleged that Xarelto caused severe intracranial bleeding which caused her grandmother to die.

Full Text of Articles Below

Client Attorney Privileged/Attorney Work Product/At Request of Counsel

Plaintiff Attorney Press Releases

Seeger Weiss LLP Reports That Xarelto Multidistrict Litigation Bellwether Trial Dates Set For Early 2017

Nov 13, 2015 | PR Newswire

By Seeger Weiss LLP

Seeger Weiss LLP is reporting that the bellwether trial dates have been set for the Xarelto Multidistrict Litigation (MDL). Presiding District Court Judge Eldon Fallon has issued an order for the first four scheduled bellwether trials to commence. The first two will be held in the Eastern District of Louisiana; the first starting on February 6, 2017, and the second starting on March 13, 2017. The next trial will be held in Mississippi on April 24, 2017. The fourth will be held in Texas onMay 30, 2017.
Xarelto has been connected to serious health issues such as gastrointestinal bleeding, brain hemorrhaging, blood clots, and stroke. Plaintiffs have alleged, in part, that the defendants responsible for developing and marketing Xarelto, Bayer Healthcare, Janssen Pharmaceuticals, and Johnson & Johnson, failed to warn doctors and patients that patients on Xarelto would require medical monitoring and that they were at an increased risk for certain types of bleeding events. Further, plaintiffs claim the manufacturers failed to notify patients that there was no reversal agent that could quickly stop the anticoagulant effects of Xarelto, thereby increasing the risk of uncontrolled bleeding in some patients.
The upcoming bellwether trials are intended to give plaintiffs and their attorneys in the remaining number of cases a better idea as to how juries will respond to certain evidence and testimonies that will be recurring throughout all similar trials.
Several partners at Seeger Weiss LLP serve as leadership in this multidistrict litigation based in the US District Court for the Eastern District of Louisiana.
Seeger Weiss LLP is one of the nation's leading trial law firms handling complex individual, mass and class action litigation on behalf of consumers, investors, injured persons and whistleblowers. The firm, with offices in New York, Philadelphia and New Jersey, represents plaintiffs throughout litigation and as trial counsel in a variety of practice areas, including financial, securities and investment fraud, pharmaceutical injury, consumer protection, qui tam (whistleblower cases), environmental and asbestos exposures, personal injury and medical malpractice, product defect, antitrust, and commercial disputes. For more information, go towww.seegerweiss.com.
For more information on Xarelto or if you believe you have been injured by using Xarelto, go to www.seegerweiss.com/drug-injury/xarelto-lawsuit.
http://www.prnewswire.com/news-releases/seeger-weiss-llp-reports-that-xarelto-multidistrict-litigation-bellwether-trial-dates-set-for-early-2017-300178348.html

Return to headline | Return to top
Xarelto Lawsuit Update: Case Numbers Rising in Philadelphia Mass Tort Group

Nov 13, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports today on the development of the Philadelphia mass tort group that was created for the ongoing Xarelto litigation. The Philadelphia mass tort group was created after a motion was made to consolidate the growing number of cases filed against the manufacturers of Xarelto in the area. There are currently 478 cases filed in the mass tort group. The number of cases filed has consistently been on the rise and is expected to continue to grow as time moves on.
The litigation is still in the pretrial and discovery stages and trials are not expected to start for quite some time. The mass tort group is consolidated in the Philadelphia court of Common Pleas’s Complex Litigation Center. For more detailed information on the litigation process, visit this page.
Allegations Made Against Xarelto Manufacturers:
The lawsuits in the Philadelphia mass tort group are able to be consolidate because they all make similar allegations against the same defendants, in this case the defendants are the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. The lawsuits filed all generally allege that Xarelto causes uncontrollable internal bleeding that can lead to serious injury and even death in patients, that the manufacturers of Xarelto failed to adequately warn patients and doctors about real dangers of the drug and provide them with information on how to stabilize patients experiencing an adverse reaction, and that the manufacturers of Xarelto were negligent in releasing the drug onto the market without a corresponding antidote. For a full list of the cases filed, click here.
Lawsuits Allege Lack of Antidote is Negligent:
These lawsuits allege that Xarelto is significantly more dangerous than other blood thinners on the market because Xarelto does not have a corresponding antidote available. This means that if a patient taking Xarelto suffers from an internal bleeding injury, that internal bleed can become uncontrollable because there is no way to stop the bleeding. This is what has led to the injury of many of the plaintiffs in the mass tort group and it is a very different situation than patients who are taking other blood thinners, such as Warfarin, are in. If a patient taking Warfarin experiences an internal bleed, a doctor will be able to simply administer vitamin K to the patient and their blood will clot again.
Lawsuits Filed Seeking Internal Bleeding and Wrongful Death Damages:
Many of the lawsuits filed in the mass tort group are internal bleeding and wrongful death lawsuits. These lawsuits are seeking compensation for damages such as the costs of medical treatment, hospital bills, loss of wages, loss of future earnings, loss of companionship, and in the case of wrongful death, funeral and burial expenses.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

http://www.digitaljournal.com/pr/2744315#ixzz3ryX4eIYb

Return to headline | Return to top
Xarelto Lawsuit Alleges Drug Caused Father’s Death

Nov 15, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on a Vermont lawsuit filed against Xarelto manufacturers Bayer AG and Janssen (a subsidiary of Johnson & Johnson). The suit was filed under case number 2:14-cv-00159-CR in the state’s federal court by a young woman who lost her father when he passed away from complications due to uncontrollable bleeding. The complaint filed alleges that blood thinning drug Xarelto caused the man’s uncontrollable bleeding and subsequent death.
The daughter goes on to explain that her father was prescribed Xarelto to treat his atrial fibrillation. Atrial fibrillation is a heart condition which causes the heart to beat more quickly than normal. Although the condition is not a fatal one, it can cause blood clots or strokes, so individuals with atrial fibrillation commonly use blood thinners.
After just a short time taking the medication, the man became injured and was hospitalized. At the hospital, doctors said he had suffered a parenchymal hemorrhage, and they could not stop the bleeding. Because he still had active Xarelto in his system, physicians were unable to make his blood clot. After 6 days of significant blood loss, the man passed away.
The daughter’s complaint goes on to allege that if she or her father were previously aware of this dangerous side effect of Xarelto, they would have never used the drug. She also noted that there were other blood thinners on the market at the time which now appear to be safer alternatives. This is a commonly heard statement. Many Xarelto lawsuit plaintiffs consider the drug to be the most dangerous blood thinner on the market. This is due to the fact that the drug has no corresponding antidote. Manufacturers have been termed negligent and reckless to release it without one.
If someone has Xarelto in their system and they injure themselves and begin to bleed, doctors cannot make their blood clot because of the medication. In these instances, physicians must resort to life-saving measures such as blood transfusions to attempt to keep the patient alive. Those taking traditional blood thinners who are injured and bleeding, however, are able to be given a vitamin K treatment which reverses the effects of the medication and allows their blood to clot.
Because of the recent surge in Xarelto lawsuits, which currently number somewhere around 1,700 federally, they have been consolidated for form multidistrict litigation number 2592. As the cases involved await trial, many expect others to be filed and join. Marc Goldich, Esq. is helping to ensure that anyone who has suffered adverse effects after using Xarelto has the opportunity to look into their legal rights. These people could be entitled to compensation. At this time, Attorney Goldich is offering free consultations to involved individuals.
For additional information on Xarelto bleeding lawsuits or to ask questions, please contact Marc Goldich, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2744525

Return to headline | Return to top
Legal-Bay Lawsuit Settlement Funding Reports Xarelto News: Bellwether Trial Dates Announced

Nov 16, 2015 | pharmiweb.com

By Legal Bay

Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the first bellwether trial dates in the Xarelto multidistrict litigation have been announced. U.S. District Judge Eldon Fallon will be overseeing the cases, and an order states that cases will be selected in January of 2016 from 40 lawsuits. Cases will be selected according to readiness for trial. According to an article on Reuters, the first two trials will take place in the U.S. District Court in the Eastern District of Louisiana on February 6th and March 13th of 2017. The third trial will be heard in Mississippi on April 24th, 2017 and the fourth will take place in Texas on May 30th, 2017.
Logo - http://photos.prnewswire.com/prnh/20140714/126845
The Xarelto lawsuits have now risen to approximately 1,700 filed cases against Bayer and Johnson & Johnson's subsidiary, Janssen Pharmaceutical Division. The lawsuits include claims of serious health problems and even death as a result of using the blood thinner, Xarelto, because of uncontrollable bleeding events. According to experts, there is no known antidote at this time. Due to the ongoing Xarelto MDL, Legal-Bay, a law cash advance company, is reaffirming the fact that they are sufficiently prepared to handle large Xarelto pre-settlement funding requests for those who have experienced complications from using the blood thinner.
Chris Janish, CEO of Legal-Bay, commented on the recent announcement in the Xarelto multidistrict litigation, "In a short amount of time, the lawsuits filed against Bayer and Johnson & Johnson's Janssen Pharmaceutical Division have risen to over 1,700 cases. With the first bellwether trial dates in the Xarelto litigation now set for 2017, we urge patients who have been injured by the blood thinner to contact a lawyer immediately if they have not done so already, as this litigation could drag on for years."
In order to receive lawsuit funding you must have retained a Xarelto lawyer first. If you need lawsuit money or pre-settlement funding for your Xarelto claim, Legal-Bay is here to help. Legal-Bay is offering pre-settlement and settlement funding for Xarelto cases as well as other blood thinners – such as Pradaxa – and they are also providing free legal consultations for possible plaintiffs who have not yet retained a Xarelto lawyer. To learn more about Xarelto, Pradaxa, and other blood thinner cases, including services in helping you find a Xarelto lawyer or Xarelto law firm, visit: http://lawsuitssettlementfunding.com/pradaxa-settlement-funding.php
Legal-Bay is advising victims who have had complications after using the blood thinner, Xarelto, to seek immediate legal counsel to determine if they may have a potential claim against Bayer and Johnson & Johnson's Janssen Pharmaceutical Division. Legal-Bay's representatives can put you in touch with a Xarelto attorney who will provide you with a free legal consultation and you will never pay a fee unless your case is successful. Legal-Bay also provides funding and lawsuit help services for other drug cases as well as defective product cases. For more information or assistance with finding a qualified Xarelto law firm or Xarelto lawyer, contact Legal-Bay directly at: http://lawsuitssettlementfunding.com/contact-us.php
To speak with a live agent to discuss receiving pre-settlement lawsuit money or a free legal consultation on your potential Xarelto or Pradaxa blood thinner lawsuit, call Legal-Bay's toll-free hotline at: 877.571.0405.
You may also apply online at: http://lawsuitssettlementfunding.com and an agent will respond to your request shortly.
http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=139499#.Vk49fXarRD8

Return to headline | Return to top
Xarelto Lawsuit Bellwether Trial Updates

Nov 16, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on the latest news concerning Xarelto lawsuit bellwether trials. These trials are being overseen by United States District Judge Eldon Fallon. A recent order additionally states that bellwether trial cases will be selected in January of 2016 from a group of 40 filed suits. The selections will be made based on which seem most ready for trial. It has been announced that the first 2 of 4 bellwether trials will take place in the U.S. District Court of the Eastern District of Louisiana on February 6th, 2017, and March 13th, 2017. The third Xarelto bellwether trial is set to be heard in Mississippi on April 24th,2017, while the fourth and final bellwether trial will be heard in Texas on May 30th,2017.
On a federal level, Xarelto lawsuits currently make up over 1,700 filed cases. Complaints are filed against defendants Bayer AG and Janssen Pharmaceuticals (a subdivision of Johnson & Johnson). They were formed into multidistrict litigation number 2592, and all contain similar allegations that the blood thinning drug caused uncontrollable bleeding events. Many plaintiffs call Xarelto the most dangerous blood thinner on the market, due to the fact that it was developed and sold without a corresponding antidote.
Because the drug has no antidote, if someone taking it is injured and bleeds, there is nothing physicians can do to reverse the effects of the drug and get that person’s blood to clot. In these instances, they have to resort to life-saving measures to keep the person alive. With traditional blood thinners, however, these risks are not as severe. When someone taking a traditional blood thinner is injured and bleeds, physicians can administer vitamin K. Unlike Xarelto, traditional blood thinners respond to vitamin K, which counters their effects and allows blood to clot, thus preventing uncontrollable bleeding episodes, and even bleed outs.
Because of these dangers, many have stepped up to file suit against the drug. Xarelto is the subject of over 2,000 lawsuits: more than 1,700 which have been federally filed and consolidated to form the MDL, and more than 300 which are part of a mass tort in Philadelphia, Pennsylvania. It is fully expected that as these cases await trial, others will continue to be filed.
Marc Goldich, Esq. is working to assist individuals who would like to explore their legal rights concerning Xarelto lawsuits. Those who have taken the drug and who have suffered adverse health effects that they attribute to the drug may be entitled to compensation. Anyone involved is currently being offered free legal consultations.
For additional information concerning Xarelto lawsuits, or to ask questions, please call Marc Goldich, Esq. at 866-425-8902.
http://www.digitaljournal.com/pr/2745922

Return to headline | Return to top
Xarelto Lawsuit Questions Drug’s Once-Daily Dosage

Nov 17, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on a new type of Xarelto lawsuit which was filed in Pennsylvania State Court. The suit, filed against Janssen Pharmaceuticals (a division of Johnson & Johnson), brings a new argument to the table against blood-thinner Xarelto. It alleges that the recommended once-daily dosage of the drug is not effective for 24-hours as indicated. Supporting evidence of this is found in details of the suit, which discuss a plaintiff who suffered a stroke just four days after starting to use Xarelto in order to prevent a stroke due to his atrial fibrillation condition.
Xarelto is unlike other blood thinners on the market today with its one pill a day, one-size-fits-all dosing. Other blood thinners require 2 doses of medication daily. After having a stroke, the plaintiff in this case filed a suit against the drug and manufacturer on October 8th of 2015. His complaint is the first of its kind concerning Xarelto, however, there are many other lawsuits which similarly allege the drug is problematic. Most commonly, it has been alleged that Xarelto causes increased risk for uncontrollable bleeding injuries and even death.
In this particular suit, the plaintiff not only states that the drug was ineffective in preventing his stroke as it was supposed to do, but he also alleges that the medication may have actually caused his stroke. Across the nation, Xarelto has been the subject of more than 1,700 federal lawsuits and over 300 suits in a mass tort in Philadelphia.
Xarelto was approved by the United States Food and Drug Administration in 2011 to prevent strokes and blood clots for individuals with atrial fibrillation, and also those recovering from knee and hip surgeries. The drug is supposed to help ensure that these patients do not develop blood clots such as deep vein thrombosis or pulmonary embolism. Initially, consumers were enticed to use Xarelto due to the fact that, unlike more traditional blood thinners, the drug did not require regular evaluations by a physician, or a special diet.
As allegations in the many pending suits have brought to light, a major problem with the new type of blood thinner, however, was that it was released to the market with no corresponding antidote. Individuals using the drug who begin to bleed will be unable to get their blood to clot. Physicians treating patients in this situation have to resort to life-saving measures such as blood transfusions. Traditional blood thinners are different in this way, as well. The effects of these anticoagulants are able to be reversed with vitamin K treatments. If someone using a traditional blood thinner begins to bleed, doctors can treat them with vitamin K and their blood will clot.
At this time, Xarelto lawsuits have been consolidated for form multidistrict litigation number 2592.They are being overseen by the Honorable U.S. District Judge Eldon E. Fallon, and bellwether trials for the cases are expected to begin in August of 2016. It is fully anticipated that as the MDL cases await bellwether trials, additional lawsuits against Xarelto will be filed.
Marc Goldich, Esq. is working to help ensure that individuals suffering after using Xarelto are able to explore their legal rights. He is offering free consultations to those involved, who may be entitled to compensation. For additional information or questions, contact Marc Goldich, Esq. by calling 877-635-5876.
http://www.digitaljournal.com/pr/2747667

Return to headline | Return to top
Xarelto Lawsuit Update: Information About Statute of Limitations for Xarelto Cases

Nov 17, 2015 | KUSA-TV

By Marc Goldich

BloodThinnerHelp.com reports today with information on the statute of limitations for Xarelto lawsuits. The statute of limitations are especially important to be aware of because they vary from state to state and once they expire, the plaintiff is barred from bringing a Xarelto lawsuit forward.
The statutes of limitations are sets of laws on the books in every state that dictate the amount of time in which a plaintiff has to bring a lawsuit forward. The amount of time begins when the event in question occurred or when it should have been discovered. There are different time periods allocated for different situations and if the plaintiff does not file a lawsuit within this time period, they will be permanently barred form recouping damages for that particular injury. For more detailed information on the Xarelto litigation, click here.
The statutes of limitations make time of the essence when it comes to Xarelto lawsuits. Xarelto lawsuits are considered defective product lawsuits and since the statutes of limitation vary from state to state, we have listed the statute of limitations for defective products cases for several states below:
Defective Product Lawsuits in Pennsylvania – 2 years from date of injury
Defective Product Lawsuits in New Jersey – 2 years from date of injury
Defective Product Lawsuits in California – 2 years from date of injury
Defective Product Lawsuits in New York – 3 years from date of injury
Defective Product Lawsuits in Washington D.C. – 3 years from date of injury
Many Lawsuits Filed Against Xarelto’s Manufacturers:
There are currently over 1,200 lawsuits filed against the manufacturers of Xarelto, Bayer AG and Janssen pharmaceuticals, a subdivision of Johnson&Johnson. The federally filed lawsuits are currently consolidated in a multidistrict litigation, MDL, in the United States District Court for the Eastern District of Louisiana presided over by Judge Eldon Fallon. There are also about 400 lawsuits consolidated in a mass tort group in the Philadelphia Court of Common Pleas.
These lawsuits all commonly allege that Xarelto causes uncontrollable internal bleeding which can lead to severe injuries and death in some patients. Further, the lawsuits allege that the manufacturers of Xarelto failed to adequately warn doctors and patients about the true dangers of Xarelto and that the manufacturers were reckless and negligent in releasing a drug to the market without a corresponding antidote and without informing doctors on how to stabilize patients who are having an adverse reaction.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.kusi.com/story/30540999/xarelto-lawsuit-update-information-about-statute-of-limitations-for-xarelto-cases

Return to headline | Return to top
Xarelto Lawsuit Update: New Xarelto MDL Pretrial Order Released

Nov 17, 2015 | KFJX-TV

By Marc Goldich

BloodThinnerHelp.com reports today with an update from the Xarelto multidistrict litigation. On October 21, 2015, Pretrial Order 15B was released by presiding Judge Eldon Fallon. The order is in regards to the preservation of voice mail, text messages, and instant messages that may be pertinent to the Xarelto litigation. More specific information about the ongoing Xarelto litigation can be found on this page.
Specifically, in Pretrial Order 15, the plaintiffs and defendants agreed that the parties will continue to meet and discuss their obligation that all parties have to preserve relevant voicemails, instant messages set or received on an instant messaging system, or text messages sent or received on a cellular phone, smartphone, tablet, or other mobile device for the trial. The full Pretrial Order can be found online here.
Details of the Xarelto MDL:
The Xarelto MDL was formed in December 2014 after a motion was made to consolidate the rising number of cases filed against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals. Consolidating the cases in the MDL is a way to save time and judicial resources for all parties involved. It streamlines the pretrial discovery and trial processes. The lawsuits were able to be consolidated into this litigation management system because they all made similar allegations against the same defendants. These lawsuits are alleging that the blood thinner Xarelto causes serious internal bleeding which can lead to severe, life changing injuries and even death in some patients. Further, they allege that the manufacturers failed to adequately warn patients about the true dangers of the drug and that they were negligent in releasing the drug to market without a corresponding antidote. The lawsuits allege that this is what makes Xarelto particularly dangerous, more dangerous than the other blood thinners available on the market.
Lawsuits Allege Xarelto’s Lack of Antidote is Dangerous:
Unlike traditional blood thinners available on the United States drug market, such as Warfarin, Xarelto does not have a corresponding antidote to reverse its anticoagulant effects. This is dangerous because if a patient taking Xarelto suffers from an internal bleeding injury, there is no medical way to stop the bleeding short of extreme live saving measures. This is very different for patients who are taking traditional blood thinners, like warfarin, and experience an internal bleed. In that event, a doctor can simply administer vitamin K and the patient’s blood will clot again.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.fox14tv.com/story/30531053/xarelto-lawsuit-update-new-xarelto-mdl-pretrial-order-released

Return to headline | Return to top
Xarelto Lawsuit Alleges Drug Caused Vermont Man's Parenchymal Hemorrhage And Death

Nov 17, 2015 | WHNS-TV

By Marc Goldich

BloodThinnerHelp.com reports on details from another lawsuit filed against blood-thinning drug Xarelto and manufactureres Janssen Pharmaceuticals and Bayer AG. The suit is just one of many which similarly allege that Xarelto causes uncontrollable bleeding that can lead to severe injury or death. The suit was filed under case number 2:14-cv-00159-cr in Vermont federal court on July 25th of last year. It was filed by a daughter for her father, who had died due to a parenchymal hemorrhage which his family alleges was caused by his use of Xarelto.
Details within the lawsuit explain that the father was admitted to the hospital and diagnosed with a parenchymal hemorrhage, however, physicians were unable to get the man to stop bleeding. His blood would not clot due to the fact that there was active Xarelto in his system. Because the drug has no antidote, physicians were unable to counter its effects. The man had taken Xarelto for less than one month when he died due to his uncontrollable internal bleeding on the 1st of August, 2012.
The man’s daughter, now representing her father in the current lawsuit, is looking to gain compensation for his wrongful death. As the administrator of her father’s estate, she is seeking damages for the cost of medical and funeral fees, as well as pain and damages. She states clearly in the suit that, had she and her father known about the dangers allegedly associated with Xarelto, they would have chosen a safer alternative to treat him. She also makes note that it shows negligence and recklessness that the manufacturers moved forward with releasing the drug to the market without any corresponding antidote.
Traditional blood thinners, such as warfarin, do not have this problem. When patients who have traditional blood thinners in their system are injured and bleeding, physicians are able to treat them with vitamin K, which counteracts the effects of the medication and allows their blood to clot. Xarelto does not respond to vitamin K, or to anything for that matter. Because it has no antidote, physicians have to treat patients who are bleeding with Xarelto in their systems by resorting to life-saving measures such as blood transfusions in an attempt to keep them alive. For this reason, Xarelto is widely considered the most dangerous blood thinner currently on the market.
Xarelto has been the subject of over 2,000 lawsuits across the country. Around 1,700 of these suits are in federal court and have been consolidated to form multidistrict litigation number 2592. Additionally, there is a mass tort group of several hundred cases in Philadelphia, Pennsylvania. As lawsuits concerning the drug began to mount, the U.S. Food and Drug Administration issued several warnings regarding the product.
Attorney Marc Goldich is working to ensure that anyone who has suffered adverse health effects after using Xarelto is able to explore their full legal rights. These individuals may be entitled to compensation. Currently, Attorney Goldich is offering free consultations to those involved.
To ask questions regarding this release, or to obtain additional information on the pending Xarelto litigation, please contact Marc Goldich, Esq. at (866) 425-8902.
http://www.foxcarolina.com/story/30553306/xarelto-lawsuit-alleges-drug-caused-vermont-mans-parenchymal-hemorrhage-and-death

Return to headline | Return to top
Xarelto Lawsuit Update: Information About Statute of Limitations for Xarelto Cases

Nov 17, 2015 | KUSA-TV

By Marc Goldich

BloodThinnerHelp.com reports today with information on the statute of limitations for Xarelto lawsuits. The statute of limitations are especially important to be aware of because they vary from state to state and once they expire, the plaintiff is barred from bringing a Xarelto lawsuit forward.
The statutes of limitations are sets of laws on the books in every state that dictate the amount of time in which a plaintiff has to bring a lawsuit forward. The amount of time begins when the event in question occurred or when it should have been discovered. There are different time periods allocated for different situations and if the plaintiff does not file a lawsuit within this time period, they will be permanently barred form recouping damages for that particular injury. For more detailed information on the Xarelto litigation, click here.
The statutes of limitations make time of the essence when it comes to Xarelto lawsuits. Xarelto lawsuits are considered defective product lawsuits and since the statutes of limitation vary from state to state, we have listed the statute of limitations for defective products cases for several states below:
Defective Product Lawsuits in Pennsylvania – 2 years from date of injury
Defective Product Lawsuits in New Jersey – 2 years from date of injury
Defective Product Lawsuits in California – 2 years from date of injury
Defective Product Lawsuits in New York – 3 years from date of injury
Defective Product Lawsuits in Washington D.C. – 3 years from date of injury
Many Lawsuits Filed Against Xarelto’s Manufacturers:
There are currently over 1,200 lawsuits filed against the manufacturers of Xarelto, Bayer AG and Janssen pharmaceuticals, a subdivision of Johnson&Johnson. The federally filed lawsuits are currently consolidated in a multidistrict litigation, MDL, in the United States District Court for the Eastern District of Louisiana presided over by Judge Eldon Fallon. There are also about 400 lawsuits consolidated in a mass tort group in the Philadelphia Court of Common Pleas.
These lawsuits all commonly allege that Xarelto causes uncontrollable internal bleeding which can lead to severe injuries and death in some patients. Further, the lawsuits allege that the manufacturers of Xarelto failed to adequately warn doctors and patients about the true dangers of Xarelto and that the manufacturers were reckless and negligent in releasing a drug to the market without a corresponding antidote and without informing doctors on how to stabilize patients who are having an adverse reaction.
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.kusi.com/story/30540999/xarelto-lawsuit-update-information-about-statute-of-limitations-for-xarelto-cases

Return to headline | Return to top
Xarelto Lawsuit Updates Show An Increase In Mass Tort Filings

Nov 18, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on recent developments showing an increase in the lawsuits filed against blood-thinner Xarelto in Philadelpha’s mass tort group. The group was created in Philadelphia, Pennsylvania after a motion was made to consolidate the growing cases, which now number around 478. Federally, they are joined by over 1,700 cases filed against the drug. All cases similarly allege that Xarelto causes uncontrollable bleeding. Since this consolidation and the formation of MDL 2592 with all federal cases, additional cases have been increasingly appearing.
Xarelto litigation is still in discovery and pretrial stages, and it will likely take some time for trials to begin. It is expected that in the meantime, cases will continue to be filed. Cases filed in the PA mass tort group have been consolidated in the Philadelphia Court of Common Pleas’ Complex Litigation Center.
Allegations are made against defendants Bayer AG and Janssen Pharmaceuticals, (a division of pharmaceutical giant Johnson & Johnson). Details within the suits commonly allege that the drug, which offers no antidote at this time, can cause serious bleeding injuries and even death in those using it. Plaintiffs also state that the medication’s manufacturers failed to adequately warn consumers and physicians of the risks associated with their drug. They claim that it is negligent to release the drug to the market without being able to release a corresponding antidote.
Many consider Xarelto to be the most dangerous blood thinner on the market at this time. The fact that it has no antidote means that if someone taking the drug becomes injured and begins to bleed, the bleed can become uncontrollable because the drug will not allow that person’s blood to clot. In these instances, physicians can do nothing to get the blood to clot, and have to resort to life-saving measures such as blood transfusions.
Individuals taking traditional blood thinners, such as warfarin, have an antidote available. These types of blood thinners respond to vitamin K. If these patients are injured and bleeding, doctors can administer vitamin K, counteracting the effects of the drug and allowing their blood to clot.
Many of the lawsuits which have been filed in Philadelphia’s mass tort group cite internal bleeding and wrongful death. The plaintiffs and families involved are seeking compensation for medical bills, lost wages and future earnings, loss of companionship, and even funeral and burial expenses.
Due to the fact that other cases are expected to continue to be filed, Marc Goldich, Esq. is working to help ensure that individuals involved are able to explore their legal rights. Anyone who has taken Xarelto and suffered adverse health events may be entitled to compensation. Attorney Goldich is offering free legal consultations to these individuals at this time.
For questions regarding this press release, or to obtain more information concerning the pending Xarelto litigation, please contact Marc Goldich, Esq. at (866) 425-8902.
http://www.digitaljournal.com/pr/2749756

Return to headline | Return to top
Xarelto Lawsuit Plaintiff Seeks Compensation From Manufacturers

Nov 19, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on another lawsuit filed against blood-thinning drug Xarelto, as well as drug developers, researchers, and manufacturers Bayer AG and Johnson & Johnson which alleges that they fraudulently misrepresented risks, dangers, and benefits associated with the drug. This particular filing was a 32-count complaint. It was filed on October 13th in St. Clair County Circuit Court.
Details within the complaint allege that all defendants failed to properly warn physicians as well as health care providers of the significant dangers and risks connected to the drug. Additionally, the plaintiff alleges that they knowingly exaggerated Xarelto’s benefits when compared with other options available on the market.
Xarelto is widely considered the most dangerous blood thinner on the market, and has been the subject of over 1,700 federally-filed lawsuits. Plaintiffs consider it significantly dangerous due to the fact that it was released to the market without a corresponding antidote. The lack of antidote means that if a patient who is taking Xarelto becomes injured and bleeds, doctors will not be able to counter the effects of the drug and get their blood to clot. In these cases, physicians have to resort to life-saving measures such as blood transfusions to try to keep the patients alive.
Traditional blood thinners such as warfarin do not have this problem. If a patient who is taking a traditional blood thinner becomes injured and bleeds, doctors can treat them with vitamin K which counters the drug’s effects and makes their blood clot.
In this particular case, the plaintiff is seeking more than $50,000 in compensation from the defendants, plus coverage of attorney and litigation fees. His case is filed under St. Clair County Circuit Court number 15-L-581.
Many other similar lawsuits have been filed against Xarelto, both federally and within a mass tort group in Philadelphia, Pennsylvania. Since the cases were consolidated to form multidistrict litigation federally, numbers have grown even more. As these cases await trial, it is anticipated that additional Xarelto lawsuits will be filed, also alleging that the drug causes uncontrollable bleeding.
Attorney Marc Goldich is working to help ensure that anyone who has suffered adverse health effects after taking Xarelto is able to explore their legal rights. These individuals may be entitled to compensation. Marc Goldich, Esq. is offering free legal consultations to those involved.
To obtain additional information on Xarelto litigation, or to ask questions, contact Marc Goldich, Esq. directly by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2751192

Return to headline | Return to top
Xarelto Lawsuit Numbers Explode According To Court Documents

Nov 19, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports on the recent surge of Xarelto uncontrollable bleeding lawsuits, according to numbers from court documents. It was reported that in August alone, 400 cases were filed. Those involved in the litigation anticipate that additional claims will continue to be filed as time goes by.
The MDL was created by the U.S. Judicial Panel on Multidistrict Litigation in December of 2014, when they announced that all federally-filed Xarelto lawsuits against manufacturers Bayer AG and Janssen Pharmaceuticals (a division of Johnson & Johnson) would be consolidated to a single court. The MDL cases are being overseen by U.S. District Judge Eldon Fallon in the Eastern District of Louisiana.
The federally-filed MDL cases now number over 1,700, and are accompanied by a group of mass tort cases in Philadelphia, PA, which number over 400. Together, there have been over 2,000 lawsuits filed against blood thinner Xarelto from plaintiffs across the U.S. who all similarly allege that the drug causes an increased risk of uncontrollable bleeding.
A series of four bellwether trial dates have been set by Judge Fallon, which will begin in 2017. These cases will set the tone for many others that follow. According to court documents, the first two bellwether trials will take place in the Eastern District of Louisiana on February 6th and March 13th of 2017. The third bellwether trial is set to be presided over in Mississippi on April 24th of the same year, and the fourth will take place in Texas on May 30th, 2017. These four cases will be selected from a pool of over 40 based on their preparedness for trial.
Blood-thinner Xarelto has caused much of this stir due to the fact that it was released to market with no corresponding antidote. This means that if someone taking Xarelto begins to bleed, physicians will not be able to get their blood to clot. In these cases, doctors use life-saving measures like blood transfusions to attempt to save patient’s lives. Traditional blood thinners do not have this risk. They respond to vitamin K, which reverses their effects and allows blood to clot, making it easier to save bleeding patients who are using traditional blood thinners.
Currently, Attorney Marc Goldich is working to ensure that as the cases in the current MDL await trial, anyone who has taken Xarelto and has experienced adverse health effects from the drug is able to explore their full legal rights. These individuals may be entitled to compensation. Marc Goldich, Esq. is offering free consultations to those involved.
For questions, or to obtain additional information concerning the pending Xarelto litigation, please contact Marc Goldich, Esq. by calling (866) 425-8902.
http://www.digitaljournal.com/pr/2751193

Return to headline | Return to top
Xarelto Lawsuit Plaintiff Seeks Compensation From Manufacturers

Nov 19, 2015 | KOLD-TV

By Marc Goldich

BloodThinnerHelp.com reports on another lawsuit filed against blood-thinning drug Xarelto, as well as drug developers, researchers, and manufacturers Bayer AG and Johnson & Johnson which alleges that they fraudulently misrepresented risks, dangers, and benefits associated with the drug. This particular filing was a 32-count complaint. It was filed on October 13th in St. Clair County Circuit Court.
Details within the complaint allege that all defendants failed to properly warn physicians as well as health care providers of the significant dangers and risks connected to the drug. Additionally, the plaintiff alleges that they knowingly exaggerated Xarelto’s benefits when compared with other options available on the market.
Xarelto is widely considered the most dangerous blood thinner on the market, and has been the subject of over 1,700 federally-filed lawsuits. Plaintiffs consider it significantly dangerous due to the fact that it was released to the market without a corresponding antidote. The lack of antidote means that if a patient who is taking Xarelto becomes injured and bleeds, doctors will not be able to counter the effects of the drug and get their blood to clot. In these cases, physicians have to resort to life-saving measures such as blood transfusions to try to keep the patients alive.
Traditional blood thinners such as warfarin do not have this problem. If a patient who is taking a traditional blood thinner becomes injured and bleeds, doctors can treat them with vitamin K which counters the drug’s effects and makes their blood clot.
In this particular case, the plaintiff is seeking more than $50,000 in compensation from the defendants, plus coverage of attorney and litigation fees. His case is filed under St. Clair County Circuit Court number 15-L-581.
Many other similar lawsuits have been filed against Xarelto, both federally and within a mass tort group in Philadelphia, Pennsylvania. Since the cases were consolidated to form multidistrict litigation federally, numbers have grown even more. As these cases await trial, it is anticipated that additional Xarelto lawsuits will be filed, also alleging that the drug causes uncontrollable bleeding.
Attorney Marc Goldich is working to help ensure that anyone who has suffered adverse health effects after taking Xarelto is able to explore their legal rights. These individuals may be entitled to compensation. Marc Goldich, Esq. is offering free legal consultations to those involved.
To obtain additional information on Xarelto litigation, or to ask questions, contact Marc Goldich, Esq. directly by calling (866) 425-8902.
http://www.tucsonnewsnow.com/story/30562402/xarelto-lawsuit-plaintiff-seeks-compensation-from-manufacturers

Return to headline | Return to top
Xarelto Lawsuit Plaintiffs Note 4 Years Later, Still No Antidote

Nov 20, 2015 | WHNS-TV

By Marc Goldich

BloodThinnerHelp.com reports on Xarelto lawsuits filed, which now total more than 2,000 cases nationally. These cases are comprised of over 1,700 federal filings, which have been consolidated to form multidistrict litigation number 2592, as well as around 500 cases in Philadelphia, Pennsylvania’s mass tort group. Lawsuits across the board similarly allege that blood-thinner Xarelto causes uncontrollable bleeding episodes, which have sometimes resulted in death.
Many of the allegations surrounding the dangers of Xarelto specifically cite the fact that the drug has no corresponding antidote. If a patient that is taking Xarelto becomes injured and bleeds, physicians will be unable to counter Xarelto’s effects and clot the patient’s blood. In these circumstances, doctors must resort to life-saving measures such as blood transfusions in an attempt to keep the patient alive. Losing too much blood is incredibly dangerous and can result in death. Traditional blood thinners do not pose the same danger. They respond to vitamin K treatments, so that if someone taking a traditional blood thinner becomes injured and bleeds, doctors administer vitamin K to reverse the medicine’s effects and clot their blood more easily.
Many of the Xarelto lawsuits filed are against manufacturer Janssen Pharmaceuticals, a subsidiary company of pharmaceutical conglomerate Johnson & Johnson. Generally, the medication is given to patients who are at increased risk of blood clots and stroke due to atrial fibrillation, or those who may be recovering from hip and knee replacement surgeries.
Several studies have additionally supported plaintiff’s arguments in these cases. A 2014 study published by the Journal of the American Medical Association found that rivaroxaban [Xarelto] was, in fact, connected to “severe, symptomatic liver injury.” Additionally, a British Medical Journal stated that their seemed to be a “twofold higher risk of bleeding with rivaroxaban [Xarelto] as compared with warfarin.” Many plaintiffs noted that, had they been made aware of these dangers and of safer alternatives on the market, they would have never used Xarelto.
As lawsuits concerning the drug surpass 2,000 both federally and through Pennsylvania’s mass tort action, those involved suspect that this is just the beginning. Additional lawsuits are expected to be filed. As they are, Attorney Marc Goldich is working to ensure that anyone who used Xarelto and subsequently experienced adverse side effects has the opportunity to explore their legal rights. These individuals may be entitled to compensation, and are being offered free legal consultations by Attorney Goldich.
For additional information regarding Xarelto bleeding lawsuits, or to ask questions, contact Marc Goldich, Esq. at your convenience by calling 866-435-8902.
http://www.foxcarolina.com/story/30571338/xarelto-lawsuit-numbers-have-surpassed-2000-cases-total

Return to headline | Return to top
Xarelto Lawsuit Plaintiffs Question Lack of Antidote

Nov 20, 2015 | KFMB-TV

By Marc Goldich

BloodThinnerHelp.com reports on lawsuits filed against Bayer AG and Janssen Pharmaceuticals (a division of pharmaceutical conglomerate Johnson & Johnson), which question blood-thinning drug Xarelto’s market release without corresponding antidote. The suits note that the lack of antidote, which is still the case today, is irresponsible and negligent. The drug, despite it’s lack of antidote, has been on the market for four years now, and has also become the subject of an increasing number of lawsuits which connect it to uncontrollable bleeding and death.
The lack of antidote means that when a patient who has Xarelto in their system is injured and starts to bleed, physicians are unable to reverse the drug’s effects to get that patient’s blood to clot. This can put the patient at serious risk for uncontrollable bleeding. In these cases, doctors resort to life-saving measures such as blood transfusions in an attempt to save the patient’s life.
Traditional blood thinners do not have this problem. Their effects can be countered by vitamin K. When patients who use traditional blood thinners such as warfarin are injured and bleeding, physicians administer vitamin K, and the patient’s blood will clot. This can be a truly life-saving difference, and is also the reason that many allege Xarelto to be the most dangerous blood thinner currently on the market.
Anyone who has used Xarelto and who has suffered adverse health effects that they attribute to the drug may be able to file a lawsuit and may be entitled to compensation for their damages. At this time, Federal Xarelto lawsuits number over 1,700, and mass tort cases in Philadelphia have risen to over 400 cases. Together, over 2,000 plaintiffs have stepped up to sue for damages they believe to be associated with the anticoagulant. Those involved in the litigation expect additional cases to be filed as those in the MDL await trial.
As these cases continue to mount, Attorney Marc Goldich is working to help anyone involved. He offers free legal consultations for prior Xarelto patients who have suffered health issues they attribute to the drug.
For more information on Xarelto uncontrollable bleeding lawsuits, or to ask questions, contact Marc Goldich, Esq. by calling 866-425-8902.
http://www.cbs8.com/story/30571618/xarelto-lawsuit-plaintiffs-question-lack-of-antidote

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Lawsuit: Xarelto Caused Gastrointestinal Bleeding

Nov 13, 2015 | Top Class Actions

By Joanna Szabo

A Tennessee woman who developed gastrointestinal bleeding two weeks after first taking Xarelto filed a Xarelto bleeding lawsuit against Janssen Research and Development.
Plaintiff Judy S. alleges in her lawsuit that taking Xarelto caused the severe gastrointestinal bleeding that led to hospitalization and continuing treatment.
The Xarelto bleeding lawsuit claims that neither the plaintiff nor her doctor knew about the risks of excessive internal bleeding associated with Xarelto, because Janssen failed to adequately warn about those risks.
Furthermore, the lawsuit claims that had Janssen given adequate warning about the risks, the plaintiff’s doctor would not have prescribed Xarelto, nor would the plaintiff have agreed to take Xarelto. According to the Xarelto lawsuit, Janssen did not disclose the serious risks associated with Xarelto.
The Xarelto lawsuit alleges that the plaintiff’s gastrointestinal bleeding and suffering occurred because of Xarelto’s negligent and defective design, and further alleges that Janssen knew of this defective design. Specifically, Janssen allegedly knew that gastrointestinal bleeding was more common in Xarelto patients than patients who took other blood thinners.
Xarelto Bleeding Side Effects
Xarelto (rivaroxaban) is a popular blood thinner. In recent years, Xarelto has been targeted in an increasing number of Xarelto bleeding lawsuits.
More than 1,000 Xarelto lawsuits have been filed against Janssen on behalf of Xarelto users who have experienced dangerous Xarelto side effects. These side effects include gastrointestinal bleeding, hemorrhaging, and other adverse bleeding events.
Xarelto was introduced in 2011 as a replacement for Coumadin (warfarin). Xarelto was meant to help reduce the potential for blood clotting in individuals at risk for conditions such as deep vein thrombosis (DVT) or pulmonary embolism (PE).
Xarelto, unlike generic warfarin and other similar anticoagulants, does not have an available antidote to reverse or reduce the drug’s sometimes dangerous effects, which can make it much more dangerous in the event of a bleeding emergency.
Though most users of Xarelto do not experience its more severe side effects, those who do can undergo a number of potentially severe or even life-threatening bleeding issues that are made even more dangerous by the lack of an antidote.
Xarelto Bleeding Lawsuits
Many Xarelto users have chosen to respond to Janssen’s alleged negligence by filing Xarelto bleeding lawsuits, hoping to gain some kind of compensation for the pain and suffering, as well as financial loss, caused by Xarelto.
If you or someone you know has experienced Xarelto side effects such as Xarelto bleeding, you may be able to join a class action Xarelto bleeding lawsuit.
The Xarelto Bleeding Lawsuit is Case No. 2:15-cv-02277-PD, in the U.S. District Court for the Eastern District of Pennsylvania.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/220609-tennessee-woman-files-xarelto-bleeding-lawsuit/

Return to headline | Return to top
Hawaii Xarelto Bleeding Events Lawsuit

Nov 17, 2015 | Blood Thinner Help

By Marc Goldich

Xarelto is a popular anticoagulant on the market that is marketed as “one-size-fits-all” type of drug, unlike the older anticoagulants, like Warfarin that require multitudes of doctors visits and blood tests to get the correct dosage per person.
Xarelto was approved for use by the Food and Drug Administration in 2011 as a blood thinner to be used by patients who had a knee or hip replacement surgery in order to lower the chances of blood clots forming. Further approval of Xarelto was for use in people with AFib, brought on by poor blood circulation in the body, in order to lower the chances of blood clots in such patients.
Medical Studies Associate High Risk Of Internal Bleeding With Xarelto
Unfortunately, ever since Xarelto was approved the FDA, there have been multiple lawsuits that have been filed against the makers of the drug due to patients experiencing internal bleeding events. There have been medical studies undertaken that ascertain the negative effects Xarelto can have on a patient. Some of the medical study summaries are as follows:
British Medical Journal– results of their study implied that the chances of internal bleeding, more so gastrointestinal bleeding, are likely to double in individuals who are taking Xarelto as opposed to those using Warfarin.
Erasmus MC University Medical Center (Rotterdam)- this research discovered a 1.49 times rise in the possibility of someone taking Xarelto experiencing an internal bleed in comparison to someone taking Warfarin.
Baylor College of Medicine- this study released in the Clinical Cardiology in January 2015, evaluated 27,467 individuals using Xarelto for the period January 2013 to March 2014 and found that 487 of those evaluated experienced a major bleed incident, and fatally 14 of those individuals died from the internal bleeding.
Other Known Adverse Effects Of Taking Xarelto
Unlike the more traditional blood thinner Warfarin, Xarelto has no known antidote in the event that the blood is required to clot if an injury occurs. Due to Xarelto’s make up and lack of antidote, the following are some of the side effects a patient taking Xarelto may experience if injured:
Abdominal Bleeding: An internal bleeding in the abdomen can happen in the esophagus, large intestine, colon, rectum, anus, and small intestine. Depending on where the bleed is occurring the symptoms may include, light-headedness, shortness of breath, blood in the stool, and decreased blood pressure.
Brain Hemorrhage: This is a type of stroke caused by the bursting of an artery that causes localized bleeding in the surrounding tissues. This form of bleeding is known to kill brain cells. Symptoms of a brain hemorrhage will vary depending on the location of the bleeding, the intensity of the bleeding, and also the amount of tissue affected. Symptoms can develop suddenly or over time, or they can progress for the worst or suddenly happen. Symptoms can be a sudden severe headache, seizures, weakness in arm or leg, lethargy among other things.
Abnormal liver function: The JAMA Internal Medicine Journal states that Xarelto can lead to Hepatitis or abnormal liver function. Symptoms of abnormal liver function can include weakness and fatigue, weight loss, nausea and vomiting, and jaundice.
For more information about Xarelto side effects, visit our Xarelto side effects and risks page.
Drugs That Do Not Work Well With Xarelto
The FDA in early 2014 gave a warning about Xarelto stating that Xarelto should not be taken with certain types of medications. Some of these medications are:
Carbamazephine
IndinavirItraconazole
Ketoconazole
Lopinavir
Phenobarbital
Phenytoin
Rifampin
Ritonavir
St. John’s wort
Approximate Internal Bleeding Events In Hawaii & Its Major Cities
From the time Xarelto became part of the blood thinner market in 2011 over 11 million prescriptions have been
dispensed for the drug all across America. To figure out the approximate cases of internal bleeding events in Hawaii, we utilized Hawaii’s current population number of 1,419,561 and in correlation with the sum total population of America and concluded that out of the 11 million prescriptions, 48,950 of those prescriptions were from Hawaii. Furthermore, we worked out that roughly 832 of the prescriptions ended in the person taking Xarelto suffering a severe bleeding event.
We went ahead and worked out the approximate cases of internal bleeding events in Hawaii’s five major cities.
Hawaii five major cities have the following populations:
Honolulu- 371,657 population
Pearl City- 47,698 population
Hilo- 43,263 population
Kailua- 38,635 population
Waipahu- 38,216 population
Approximate Bleeding Events Correlated To Xarelto Usage In Hawaii’s Five Major Cities:
Honolulu- 218
Pearl City- 28
Hilo- 25
Kailua- 23
Waipahu- 22
How Do I Know If I Can File A Lawsuit?
Hundreds of people and families who have seen first hand the terrible side effects of Xarelto when an internal bleeding injury occurs, and are filing lawsuits against the producers of the drug, Bayer and Johnson & Johnson. Upon reading this information and are now aware that you or someone near and dear to you has had some of the events described in this article happen to them while taking Xarelto, then you have a legal right to seek justice by filing a Xarelto lawsuit. If you need to find out more information about whether or not you have a lawsuit, do not hesitate to contact us as we can help clarify some questions you may have.
Our Hawaii Xarelto legal counsel is here to assist you in this time and is available at any time of the day. Call us today for a free of charge evaluation.
http://bloodthinnerhelp.com/hawaii-xarelto-bleeding-events-lawsuit/

Return to headline | Return to top
Xarelto Bleeding Lawsuit Alleges Drug Caused Wrongful Death

Nov 19, 2015 | Top Class Actions

By Tamara Burns

A woman in Rhode Island is suing Janssen Pharmaceuticals and parent company Johnson & Johnson on behalf of her late husband who allegedly suffered personal injury and later died as a result of using the anticoagulant drug Xarelto.
Plaintiff Dorothy P. said her husband Graham P. was prescribed Xarelto by his physician and took the medication from January 2013 until February 2013 for the treatment of atrial fibrillation.
Atrial fibrillation is an irregular heartbeat that can lead to blood clots or stroke, so the medication was prescribed to Graham in hopes that he would avoid these cardiovascular events.
According to the Xarelto lawsuit, as a direct and proximate result of Xarelto, Graham suffered a cerebral hemorrhage and stroke in February 2013; he also experienced a life-threatening, irreversible bleed, pain and suffering. Graham died on February 14, 2013 as a result of these injuries.
In addition to physical damages, Graham and Patricia incurred medical expenses, the loss of accumulations, funeral expenses, probate, attorney and other administrative fees. Patricia also had other economic and non-economic damages following Graham’s death.
Patricia brings forth eleven counts against the defendants including negligence, strict products liability, breaches of express and implied warranty, fraudulent misrepresentation, fraudulent concealment, negligent misrepresentation, fraud and deceit, violation of consumer protection laws, survival action and wrongful death action.
The plaintiff is seeking compensatory, economic, and punitive damages, pre- and postjudgment interest, attorney fees and costs and other relief as deemed fair by the court.
Her Xarelto Lawsuit is Dorothy P. v. Janssen Research & Development, LLC, Case No. 3:15-cv-02774-MAS-DEA, in the United States District Court, New Jersey.
Xarelto Side Effects
Xarelto (rivaroxaban) is an anticoagulant drug used preventatively to reduce the risk of stroke and blood clots in patients with atrial fibrillation. It is also used to treat deep vein thrombosis (DVT), a condition where blood clots form in deep veins, usually in the lower extremities, and pulmonary embolism (PE), a condition that occurs when a blood clot affects the lungs.
While many doctors appeared to like new generation anticoagulants like Xarelto for their ease of administration, less frequent need for monitoring, and lack of dietary restrictions while taking the drug, Xarelto and its closely related drug counterparts have a major drawback: lack of an effective reversal agent.
All anticoagulant drugs have the side effect of bleeding complications. Because the drugs inhibit the body’s natural clotting mechanism, it is a known potential issue. The older generation anticoagulant drug, warfarin (Coumadin), however, has an effective reversal agent.
As an antidote to excessive bleeding, patients taking warfarin could be administered fresh frozen plasma and intravenous vitamin K to effectively stop the bleeding and resume clotting.
Xarelto does not currently have such an intervention to effectively stop bleeding. Essentially, patients must wait until the drug leaves their system and the blood begins clotting again. For some, the wait might be too long and the Xarelto bleed becomes fatal.
Xarelto Lawsuit Information
If you or someone you love has taken Xarelto and has suffered from gastrointestinal bleeding, pulmonary bleeding, cerebral bleeding or any other type of Xarelto bleeding, you may be eligible for legal compensation. A Xarelto lawyer will review your case at no charge to you to determine your eligibility of filing a lawsuit for your Xarelto injury.
Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/225287-xarelto-bleeding-lawsuit-filed-by-rhode-island-widow/

Return to headline | Return to top
Considering a Xarelto lawsuit? Our Dallas Xarelto lawyers will help you stand up to giant companies and get just compensation. No win no fee!

Nov 19, 2015 | Mullen & Mullen

Xarelto is marketed by Johnson & Johnson, a subsidiary of Janssen Pharmaceuticals, and is manufactured by Bayer.
Designed to treat and prevent blood clots, Xarelto (rivaroxaban) unfortunately sometimes does exactly the opposite. Instead, Xarelto can cause you to bleed internally – to the point where it’s fatal.
And if your loved one didn’t pay the ultimate price for using this drug, they may also have experienced serious side-effects like these:
Stroke
Retinal hemorrhage
Epidural hematoma (a traumatic brain injury)
Pulmonary embolism (blockage of pulmonary arteries in your longs)
Gastrointestinal hemorrhage
Diarrhea
Arrhythmia (irregular heartbeat)
Adrenal bleeding
Deep vein thrombosis (blood clots usually found in your legs)
Adrenal bleeding
If you get even just a minor injury, like bumping your head, you can even experience fatal bleeding!
You can learn more about Xarelto in this medication guide prepared by the FDA.
Hurt By Xarelto? What Can You Do?
When giant corporations like Johnson & Johnson decide to disregard how their actions affect you, what can you do?
You feel so powerless, helpless, and hopeless. They have thousands of employees, billions of dollars, and high-power attorneys ready to defend their position.
You need a personal injury lawyer who can help.
But you don’t want just any lawyer – you want the best.
Pay Nothing Unless You Win – Get Your Free Consultation Today!
At Mullen & Mullen, you only pay us when your case wins. Our Dallas Xarelto lawyers prepare your case like it’s going to trial – but 90% of all cases settle outside of court. It costs absolutely nothing to learn if your Xarelto case is one that can win in court. And you only pay our fee when you win.
To get your free consultation, contact our Dallas Xarelto lawsuit lawyers online, or call (214) 212-2495 today.
Frequently Asked Questions About Xarelto Lawsuits – Straight Answers to Tough Questions
What are Johnson & Johnson and Bayer Accused Of?
Quite a bit. Some of the allegations against these companies include:
Failing to accurately warn consumers about Xarelto’s potential to cause uncontrollable bleeding
Not telling doctors or patients about Xarelto’s lack of a reversal agent (a substance used to prevent severe hemorrhaging)
Aggressively marketing this drug to doctors, despite awareness of its risks
Selling Xarelto despite knowledge of its dangers as it was originally made
After it was clear Xarelto did cause harm to patients, failing to provide warnings
Why Are Xarelto’s Manufacturers Responsible for My Injuries?
All drug manufacturers have a legal responsibility to make sure their drugs are safe and reliable for consumer use. They took, and failed to take, reasonable action that would prevent harm to millions of consumers.
Had you or your doctor known of the risk of uncontrollable bleeding, do you think you would have taken this medication?
Is Xarelto Still Available in the Market?
Yes it is.
Despite many Xarelto lawsuits across the nation and this recent FDA decision, Xarelto continues to be sold in Europe and the US. Bayer and Johnson & Johnson make billions dollars off these sales each year.
Bayer also recently got a FDA warning for overstating the benefits of its contraceptive, Yaz. Janssen Pharmaceutica, a Belgian division of J&J that markets Xarelto, is also currently under investigation for bribing pharmacists to sell other prescription drugs.
Both Bayer and J&J companies continue to persuade the FDA to approve Xarelto for ACS treatment, which would give them access to at least 1 million more patients.
What Type of Compensation Can I Get for My Injuries?
We can’t guarantee a specific amount of compensation for any case. Legal ethics prevent us from doing so.
However, depending on your individual circumstances, you may be able to collect compensation for:
Medical bills
Lost wages
Pain and suffering
Emotional distress
Wrongful death of your loved one
I’m Afraid to Sue – I Don’t Like to Get Involved in the Legal System – Do I Need to File a Xarelto Lawsuit?
You do not have a legal obligation to file a lawsuit. You only have to file one if you want to.
However, if this drug has harmed you, you may:
Lose years of wages
Have to pay for past, present, and future medical bills
This could total millions of dollars that someone has to pay – either you or these drug companies.
When someone else intentionally acts in an irresponsible way, should you have to take responsibility for their actions?
The choice is ultimately yours. It is stressful, but our experience attorneys make it as easy as possible.
The following outlines the criteria for the Xarelto claims we accept. If any of the below applies to you, contact us now. If none of the below applies to you or your loved one, then your case would likely not be a good fit for a Xarelto lawsuit.
Our Dallas lawyers usually only accept Xarelto cases if your injury occurred while taking Xarelto or within 30 days after you stopped taking it.
If you took Xarelto for any length of time, even one day is enough AND you were diagnosed with at least one of the following injuries within 30 days of last use, then our office would appreciate the opportunity to speak with you about your case and determine if you are a good candidate for a Xarelto claim.
Our Dallas Xarelto Attorney’s Criteria For Accepting a Case
You need to have sustained your injuries while taking Xarelto or within 30 days of last use, plus had any one or more of the following happen:
Any kind of bleeding that resulted in Hospitalization or an ER visit.
Gastrointestinal bleeding
Bleeding from kidneys or other organs
Bleeding that resulted in Stroke (Not TIAs)
Bleeding that resulted in Death
If your case does not match the above criteria then our law firm will not be able to handle your Xarelto claim, but this is not to say your case lacks merit. In fact, we strongly advise you to obtain a 2nd and even 3rd legal opinion from other law firms as quickly as possible to avoid having your claim barred due to the statute of limitations expiring. Other law firms may screen claims differently and will provide you with their own advice and opinions.
http://www.mullenandmullen.com/personal-injury/dallas-xarelto-lawsuit-lawyers/

Return to headline | Return to top
Louisiana Xarelto Wrongful Death Lawsuit

Nov 19, 2015 | The Legal Examiner

By Shexad Malik MD JD

In the latest of recently filed cases, Ashlie Fluitt from Louisiana, filed a wrongful death claim on behalf of her grandmother who died as a result of catastrophic side effects from using Xarelto. According to the lawsuit, it is alleged that Xarelto caused severe intracranial bleeding which caused her grandmother to die.
The lawsuit was filed in the U.S. District Court for the Eastern District of Louisiana alleging that Hattie Deville-Goodwin’s death was caused by Bayer Healthcare and Johnson & Johnson’s Janssen subsidiary’s failure to warn about the uncontrollable bleeding side effects associated with the new-generation anticoagulant Xarelto.
Deville-Goodwin took Xarelto for treatment of deep vein thrombosis in in her leg. Two months later, Deville-Goodwin developed severe bleeding in the brain, and died shortly afterwards from the deadly intracranial hemorrhage.
Many lawsuits have been filed against Xarelto’s manufacturers and the plaintiffs claim that the companies failed to warn patients and doctors about the risks associated with Xarelto and the lack of an antidote to help stop the bleeding.
Since December 2014, all federal product liability lawsuits filed against Bayer and Johnson & Johnson over the bleeding side effects of Xarelto have been centralized and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana as part of an MDL, or multidistrict litigation.
Lawsuits against Bayer and Johnson & Johnson are consolidated in two courts, a multidistrict litigation court in the Eastern District of Louisiana and a mass tort litigation court in Philadelphia.
The MDL in Louisiana contains over 2,200 federal lawsuits, and the mass tort in Philadelphia contains more than 400 state lawsuits.
4 Xarelto Bellwether Trials Set
Judge Fallon set a series of four bellwether trials to go before juries in the Spring of 2017. As of November 15, according the data provided by the Judicial Panel Multidistrict Litigation (JPML) there are 2,266 Xarelto bleeding injury lawsuits in the Eastern District of Louisiana.
The number of Xarelto lawsuits continue to increase and be filed by individuals across the United States, alleging severe and deadly bleeding complications.
Bellwether Trials in Louisiana, Mississippi and Texas
The first two trials will be held in the Eastern District of Louisiana, on February 6 and March 13, 2017. The third trial will be held in Mississippi on April 24, 2017 and the fourth trial will be held in Texas on May 30, 2017.
According to Judge Fallon’s order, the cases that will go before juries on these dates will be pulled from a pool of 40 lawsuits to be selected in January 2016. These cases will be trial ready, with case-specific discovery, including depositions of plaintiffs, prescribing doctors, treating physicians and sales representatives of the drug makers.
What is Xarelto?
Xarelto (rivaroxoaban) was released and approved for sale in 2011 as a superior replacement for Coumadin (warfarin). Xarelto is used to reduce the risk of blood clots among patients at risk for deep vein thrombosis, pulmonary embolism and those patients at risk for a stroke with atrial fibrillation.
Atrial fibrillation is a common heart rhythm problem, which leads to embolic strokes, from blood clots that develop in the heart and travel up to the brain.
Xarelto was developed and sold jointly by Johnson & Johnson’s Janssen Pharmaceuticals subsidiary and Bayer Healthcare. Xarelto is a “direct thrombin inhibitor,” and Xarelto was released to compete with Boehringer Ingelheim’s Pradaxa, another new type of anticoagulant. Both drugs were touted as being superior and easier to use than the older blood thinner warfarin, also known as Coumadin. Coumadin was the gold standard for anticoagulants and dominated the blood thinner market for several decades.
Xarelto has the largest share of the market for anticoagulants and is considered a blockbuster drug, with annual sales over $1 Billion in the United States.
Big Problem: No Xarelto Antidote
All anticoagulants or blood thinners have a risk of bleeding and injury, but Xarelto has been linked to a significant number of injuries involving catastrophic and uncontrollable bleeds, including death.
Xarelto has been advertised heavily as being easier to use than warfarin, since it does not require regular blood monitoring. According to several recent studies, those claims may be in doubt. Medical researchers have indicated that Xarelto blood monitoring may actually help doctors identify patients at the greatest risk of bleeding.
Plaintiffs are filing bleeding lawsuits claiming that the drug manufacturers suppressed information about the lack of a reversal agent. Warfarin’s blooding thinning effects can be quickly reversed in an emergency, there is no antidote for Xarelto.
Similar Lawsuits Claims Settled For Pradaxa
Pradaxa, is another new-generation anticoagulant introduced by Boehringer Ingelheim in October 2010. In 2014, there were 3,592 serious adverse event reports involving Pradaxa, with 752 involving the death of the patient, compared with 3,331 reports associated to Xarelto bleeding problems, with 379 involving a patient death.
Similar allegations of a lack of an antidote, were raised in more than 4,000 Pradaxa lawsuits. On the eve of trial, Boehringer Ingelheim agreed to pay $650 million in Pradaxa settlements, with an average of about $150,000 per claim.
http://fortworth.legalexaminer.com/fda-prescription-drugs/louisiana-xarelto-wrongful-death-lawsuit/

Return to headline | Return to top

Full Text of Articles Below

Add recipients

Suggested